Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone

Marija Drobnjak, Iman Osman, Howard I. Scher, Melissa Fazzari, Carlos Cordon-Cardo

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Cyclin D1 is a key regulator of the G1 phase progression of the cell cycle. There is increasing evidence that deregulated cyclin D1 expression is implicated in tumorigenesis and tumor progression in certain neoplasms. Recently, it has been reported that cyclin D1 overexpression might be related to the evolution of androgen-independent disease in prostate cancer. This study was conducted to investigate patterns of cyclin D1 expression in prostate cancer samples representing different points in the natural history and treatment evolution of the disease. Association with clinical outcomes was also explored. Using immunohistochemistry, 86 radical prostatectomy specimens (53 naive and 33 after androgen deprivation) and 22 androgen- independent bone metastases were studied. We examined the difference in cyclin D1 expression in primary versus metastatic cases. In addition, we examined the association in primary cases between cyclin D1 expression and clinicopathological parameters of poor clinical outcome, including time to prostate-specific antigen relapse and Ki67 proliferative index. Cyclin D1- positive phenotype, defined as identification of positive immunoreactivity in the nuclei of ≥20% of tumor cells, was observed in 10 of 86 (11%) primary cases compared with 15 of 22 (68%) androgen-independent bone metastases (P = 0.001). There was no correlation between cyclin D1 overexpression and either Gleason score, neo-adjuvant hormone treatment, or prostate-specific antigen relapse. We observed a statistical association between cyclin D1 overexpression and high Ki67 proliferative index, defined as ≥20% of positive tumor cells (P = 0.02). These data support the hypothesis that cyclin D1 overexpression may represent an oncogenic event in androgen- independent metastatic prostate cancer to the bone.

Original languageEnglish (US)
Pages (from-to)1891-1895
Number of pages5
JournalClinical Cancer Research
Volume6
Issue number5
StatePublished - May 1 2000
Externally publishedYes

Fingerprint

Bone Neoplasms
Cyclin D1
Prostatic Neoplasms
Androgens
Prostate-Specific Antigen
Neoplasms
Ki-67 Antigen
Neoplasm Metastasis
Bone and Bones
Recurrence
Neoplasm Grading
G1 Phase
Prostatectomy
Natural History
Cell Cycle
Carcinogenesis
Immunohistochemistry
Hormones
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Drobnjak, M., Osman, I., Scher, H. I., Fazzari, M., & Cordon-Cardo, C. (2000). Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clinical Cancer Research, 6(5), 1891-1895.

Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. / Drobnjak, Marija; Osman, Iman; Scher, Howard I.; Fazzari, Melissa; Cordon-Cardo, Carlos.

In: Clinical Cancer Research, Vol. 6, No. 5, 01.05.2000, p. 1891-1895.

Research output: Contribution to journalArticle

Drobnjak, M, Osman, I, Scher, HI, Fazzari, M & Cordon-Cardo, C 2000, 'Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone', Clinical Cancer Research, vol. 6, no. 5, pp. 1891-1895.
Drobnjak, Marija ; Osman, Iman ; Scher, Howard I. ; Fazzari, Melissa ; Cordon-Cardo, Carlos. / Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 5. pp. 1891-1895.
@article{e2922de1dca248eda4caff4e97475c03,
title = "Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone",
abstract = "Cyclin D1 is a key regulator of the G1 phase progression of the cell cycle. There is increasing evidence that deregulated cyclin D1 expression is implicated in tumorigenesis and tumor progression in certain neoplasms. Recently, it has been reported that cyclin D1 overexpression might be related to the evolution of androgen-independent disease in prostate cancer. This study was conducted to investigate patterns of cyclin D1 expression in prostate cancer samples representing different points in the natural history and treatment evolution of the disease. Association with clinical outcomes was also explored. Using immunohistochemistry, 86 radical prostatectomy specimens (53 naive and 33 after androgen deprivation) and 22 androgen- independent bone metastases were studied. We examined the difference in cyclin D1 expression in primary versus metastatic cases. In addition, we examined the association in primary cases between cyclin D1 expression and clinicopathological parameters of poor clinical outcome, including time to prostate-specific antigen relapse and Ki67 proliferative index. Cyclin D1- positive phenotype, defined as identification of positive immunoreactivity in the nuclei of ≥20{\%} of tumor cells, was observed in 10 of 86 (11{\%}) primary cases compared with 15 of 22 (68{\%}) androgen-independent bone metastases (P = 0.001). There was no correlation between cyclin D1 overexpression and either Gleason score, neo-adjuvant hormone treatment, or prostate-specific antigen relapse. We observed a statistical association between cyclin D1 overexpression and high Ki67 proliferative index, defined as ≥20{\%} of positive tumor cells (P = 0.02). These data support the hypothesis that cyclin D1 overexpression may represent an oncogenic event in androgen- independent metastatic prostate cancer to the bone.",
author = "Marija Drobnjak and Iman Osman and Scher, {Howard I.} and Melissa Fazzari and Carlos Cordon-Cardo",
year = "2000",
month = "5",
day = "1",
language = "English (US)",
volume = "6",
pages = "1891--1895",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone

AU - Drobnjak, Marija

AU - Osman, Iman

AU - Scher, Howard I.

AU - Fazzari, Melissa

AU - Cordon-Cardo, Carlos

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Cyclin D1 is a key regulator of the G1 phase progression of the cell cycle. There is increasing evidence that deregulated cyclin D1 expression is implicated in tumorigenesis and tumor progression in certain neoplasms. Recently, it has been reported that cyclin D1 overexpression might be related to the evolution of androgen-independent disease in prostate cancer. This study was conducted to investigate patterns of cyclin D1 expression in prostate cancer samples representing different points in the natural history and treatment evolution of the disease. Association with clinical outcomes was also explored. Using immunohistochemistry, 86 radical prostatectomy specimens (53 naive and 33 after androgen deprivation) and 22 androgen- independent bone metastases were studied. We examined the difference in cyclin D1 expression in primary versus metastatic cases. In addition, we examined the association in primary cases between cyclin D1 expression and clinicopathological parameters of poor clinical outcome, including time to prostate-specific antigen relapse and Ki67 proliferative index. Cyclin D1- positive phenotype, defined as identification of positive immunoreactivity in the nuclei of ≥20% of tumor cells, was observed in 10 of 86 (11%) primary cases compared with 15 of 22 (68%) androgen-independent bone metastases (P = 0.001). There was no correlation between cyclin D1 overexpression and either Gleason score, neo-adjuvant hormone treatment, or prostate-specific antigen relapse. We observed a statistical association between cyclin D1 overexpression and high Ki67 proliferative index, defined as ≥20% of positive tumor cells (P = 0.02). These data support the hypothesis that cyclin D1 overexpression may represent an oncogenic event in androgen- independent metastatic prostate cancer to the bone.

AB - Cyclin D1 is a key regulator of the G1 phase progression of the cell cycle. There is increasing evidence that deregulated cyclin D1 expression is implicated in tumorigenesis and tumor progression in certain neoplasms. Recently, it has been reported that cyclin D1 overexpression might be related to the evolution of androgen-independent disease in prostate cancer. This study was conducted to investigate patterns of cyclin D1 expression in prostate cancer samples representing different points in the natural history and treatment evolution of the disease. Association with clinical outcomes was also explored. Using immunohistochemistry, 86 radical prostatectomy specimens (53 naive and 33 after androgen deprivation) and 22 androgen- independent bone metastases were studied. We examined the difference in cyclin D1 expression in primary versus metastatic cases. In addition, we examined the association in primary cases between cyclin D1 expression and clinicopathological parameters of poor clinical outcome, including time to prostate-specific antigen relapse and Ki67 proliferative index. Cyclin D1- positive phenotype, defined as identification of positive immunoreactivity in the nuclei of ≥20% of tumor cells, was observed in 10 of 86 (11%) primary cases compared with 15 of 22 (68%) androgen-independent bone metastases (P = 0.001). There was no correlation between cyclin D1 overexpression and either Gleason score, neo-adjuvant hormone treatment, or prostate-specific antigen relapse. We observed a statistical association between cyclin D1 overexpression and high Ki67 proliferative index, defined as ≥20% of positive tumor cells (P = 0.02). These data support the hypothesis that cyclin D1 overexpression may represent an oncogenic event in androgen- independent metastatic prostate cancer to the bone.

UR - http://www.scopus.com/inward/record.url?scp=0034084926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034084926&partnerID=8YFLogxK

M3 - Article

C2 - 10815912

AN - SCOPUS:0034084926

VL - 6

SP - 1891

EP - 1895

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -